Medpace Holdings Inc (MEDP) 銘柄情報

EXPECTING LOWER

Hi OJ, unfortunately I'm out of that issuse. I'm struggling with MCRB right now.
GL
MG

nice post

more, please

What do you make of this recent sale of roughly 30,000 shares of stock reported to the SEC by Stephen Ewald at Medpace Investors LLC?

Apparently the sale was timed to coincide with release of a good 1Q 2023 earnings report? They sold at around $221 per share, and the price has fallen to under $200 just a few days later.

Best wishes,

-- OJ

This forum needs some fresh posts.

I like this stock. I discovered it when I was researching publicly held contract research organizations. (This is related to my line of work as a medical writer specializing in oncology drug development.) Other CROs I discovered about the same time included Charles River Laboratories, Parexel, PPD, PRA Health Sciences, Syneos, Covance, and ICON. About the same time I also began to invest in laboratory supply houses including BioRad, Thermo-Fisher, Perkin-Elmer, and Danaher.

I first bought shares of MEDP in 2017, paying about $28 each. I've bought and sold a lot of shares since then. My current cost basis is $154 per share. At current prices, my stake in MEDP accounts for about 19% of my brokerage account, so I pay pretty close attention to ups and downs of the share price.

If anyone wishes to discuss the latest earnings report (which beat predictions on both earnings and revenue) I'd welcome the opportunity.

Cheers!

-- OJ

MEDP MEDPACE HOLDINGS INC
$214.51 +55.87 (+35.22%)
As of Oct-25-202210:10:18 AM ET

https://stockcharts.com/h-sc/ui?s=MEDP

Contract Research Organization Medpace Lifts FY22 Guidance, Highlights FY23 Outlook
By Benzinga — 7:29 AM ET 10/25/22
Medpace Holdings Inc's (NASDAQ:MEDP) Q3 revenue increased 29.8% Y/Y to $383.7 million, beating the consensus of $357.18 million, representing a backlog conversion rate of 17.7%.
On a constant currency organic basis, Q3 revenue was up 31.9%.
As of September 30, 2022, Backlog grew 20.9% to $2.2 billion. Net new business awards were $470.9 million, representing a net book-to-bill ratio of 1.23x.
Q3 EBITDA increased 48.5% to $89.3 million, or 23.3% of revenue, compared to $60.1 million, or 20.3% of revenue, a year ago.
Medpace posted an EPS of $2.05, up from $1.29 a year ago and beating the consensus of $1.47.
Financial Guidance: Medpace raised FY22 sales guidance to $1.44-$1.46 billion, versus the prior guidance of $1.405-$1.435 billion and the consensus of $1.41 billion.
EBITDA is expected to be $302-$310 million, versus the previous guidance of $268-$280 million
Medpace expects EPS of $6.88-$7.00 compared to prior guidance of $6.07-$6.36 and the consensus of $6.15.
For FY23, the company forecasts sales of $1.68-$1.74 billion, with EBITDA of $325-$350 million.
Price Action: MEDP shares traded higher by 28.13% at $203.26 in premarket on the last check Tuesday.

Company Profile
Sector Health Care
Industry Life Sciences Tools & Services
Company Location Cincinnati, OH

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.